美國居民不適用 XM 服務。

Hyundai’s India IPO will have imitators



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>RPT-BREAKINGVIEWS-Hyundai’s India IPO will have imitators</title></head><body>

Corrects to fix sourcing in the second paragraph. The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to add hyperlink.

By Shritama Bose

MUMBAI, June 17 (Reuters Breakingviews) - If Hyundai Motor's 005380.KS up to $3 billion initial public offering of its Indian business crystallises a premium valuation as easily as expected, other multinationals could rush to list their local operations in the South Asian nation.

The South Korean carmaker on Saturday filed for a listing of the unit in Mumbai. The target valuation of up to $30 billion, per Reuters citing unnamed sources, is 53 times its earnings in the 12 months ended March 2023, compared to 32 times for its larger rival Maruti Suzuki MRTI.NS and five times for its $48 billion Seoul-listed parent.

An IPO offers lots of benefits. It will crush the "Korean discount", where companies trading in Seoul are plagued by lower valuations than Asian peers because opaque conglomerates dominate the market. Hyundai also can use the new richly valued shares to strike deals in India, where it wants to sell more expensive cars and increase its share of electric vehicles.A listing outside Seoul offers some protection from any future funding squeeze at home. The default of a Legoland theme park developer, for example, caught large Korean companies off-guard in 2022 and pushed up borrowing costs.

The carmaker is the latest global company tapping aspects of what Marc Bitzer, CEO of U.S. appliance maker Whirlpool WHR.N describes as "asset arbitrage"; the company sold a 24% stake in its India unit in February. Similarly British American Tobacco BATS.L in March sold a 3.5% stake in its Indian peer ITC ITC.NS and used the $2 billion proceeds to support a $895 million share buyback.

Companies usually shy away from floating their subsidiaries because it is not efficient to manage multiple listings. The local listings of Unilever ULVR.L, Nestle NESN.S, Pfizer PFE.N, Siemens SIEGn.DE and Suzuki Motor 7269.T enjoy big premiums but many are legacy structures.The difficulty of taking a company private in India is another reason to hold back. Yet India's increasing importance as a growth market and its buoyant stocks may be changing the balance of the equation.

The case is strong for Japanese companies that are under pressure to boost shareholder value. Take Honda Motor Co 7267.T, which counts the South Asian country as its top market for motorcycles. Sumitomo Mitsui Financial Group 8316.T could consider listing its Indian shadow bank which is growing 24% year-on-year. Other foreign firms with large India businesses include Korea's Samsung Electronics 005930.KS.

Hyundai's deal is barely out of the door but bankers are salivating over the prospect of more just like it.

Follow @ShritamaBose on X


CONTEXT NEWS

Hyundai Motor's Indian unit on June 15 filed for a Mumbai initial public offering, Reuters reported the same day citing the draft prospectus. The company plans to sell up to a 17.5% stake held by its South Korean parent. No new shares will be issued.

The deal will generate proceeds of between $2.5 billion and $3 billion for the seller at a valuation of up to $30 billion, sources told Reuters. Citi, JPMorgan, HSBC, Morgan Stanley and India's Kotak Mahindra Capital are advising the company on the deal. Hyundai shares rose nearly 5% before midday in Seoul on June 17.


Graphic: Indian units of foreign companies are richly valued https://reut.rs/3Vp7cY9


Editing by Una Galani and Aditya Sriwatsav

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明